poloxalene has been researched along with Myocardial Infarction in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hunt, D | 1 |
| Carlson, GC; Farb, A; Kolodgie, FD; Virmani, R; Wilson, PS | 1 |
| Abrahams, SL; Buddemeier, K; Ennis, B; Hubbell, JP; Hursey, TL; Moy, J; Parrillo, JE; Rodriguez, ER; Schaer, GL | 1 |
| Browne, KF; Edwards, S; Fletcher, WO; Gibbons, RJ; Grines, CL; Jolly, MK; Krichbaum, D; Krueger, KA; Phelan, JM; Schaer, GL; Spaccavento, LJ | 1 |
| Bateman, TM; Browne, K; DeWood, MA; Fletcher, WO; Gibbons, RJ; Grines, CL; Kalbfleisch, JM; Magorien, RD; O'Keefe, JH; Schaer, GL | 1 |
| Cerqueira, MD; Hallstrom, AP; Martin, JS; Maynard, C; Paris, JA; Swenson, R; Weaver, WD | 1 |
| Kaufman, RJ | 1 |
| Austin, GE; Bonner, GD; Farnsworth, WV; Hunter, RL; Justicz, AG; Martino-Saltzman, D; Sink, JD; Soberman, MS; Tuvlin, MB | 1 |
1 review(s) available for poloxalene and Myocardial Infarction
| Article | Year |
|---|---|
Medical oxygen transport using perfluorochemicals.
Topics: Anemia; Angioplasty, Balloon, Coronary; Animals; Blood Substitutes; Cardioplegic Solutions; Contrast Media; Diagnostic Imaging; Dogs; Drug Combinations; Emulsions; Fluorocarbons; Humans; Hydroxyethyl Starch Derivatives; Myocardial Infarction; Neoplasms; Oxygen; Poloxalene; Radiation-Sensitizing Agents; Respiratory Therapy; Rodentia; Shock, Hemorrhagic; Surface-Active Agents | 1991 |
5 trial(s) available for poloxalene and Myocardial Infarction
| Article | Year |
|---|---|
Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Angioplasty, Balloon, Coronary; Coronary Angiography; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Injections; Male; Middle Aged; Myocardial Infarction; Placebos; Poloxalene; Salvage Therapy; Technetium Tc 99m Sestamibi; Thrombolytic Therapy; Treatment Outcome | 1996 |
Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Creatinine; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Poloxalene; Prospective Studies; Surface-Active Agents; Treatment Outcome | 1996 |
Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Collaborative Organization for RheothRx Evaluation (CORE).
Topics: Acute Kidney Injury; Coronary Angiography; Creatinine; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Poloxalene; Surface-Active Agents; Survival Rate; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Vascular Patency; Ventricular Function, Left | 1997 |
Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group.
Topics: Acute Kidney Injury; Coronary Circulation; Electrocardiography; Fibrinolytic Agents; Follow-Up Studies; Humans; Infusions, Intravenous; Kidney Function Tests; Myocardial Infarction; Poloxalene; Stroke Volume; Treatment Failure; Treatment Outcome; Ventricular Function, Left | 1998 |
Medical oxygen transport using perfluorochemicals.
Topics: Anemia; Angioplasty, Balloon, Coronary; Animals; Blood Substitutes; Cardioplegic Solutions; Contrast Media; Diagnostic Imaging; Dogs; Drug Combinations; Emulsions; Fluorocarbons; Humans; Hydroxyethyl Starch Derivatives; Myocardial Infarction; Neoplasms; Oxygen; Poloxalene; Radiation-Sensitizing Agents; Respiratory Therapy; Rodentia; Shock, Hemorrhagic; Surface-Active Agents | 1991 |
4 other study(ies) available for poloxalene and Myocardial Infarction
| Article | Year |
|---|---|
ISIS 5 possibilities.
Topics: Adrenergic beta-Antagonists; Glucose; Heparin; Hirudin Therapy; Humans; Insulin; Myocardial Infarction; Poloxalene; Potassium; Randomized Controlled Trials as Topic; Thrombolytic Therapy | 1993 |
Hyperoxic reperfusion is required to reduce infarct size after intravenous therapy with perfluorochemical (Fluosol-DA 20%) or its detergent component (poloxamer 188) in a poorly collateralized animal model. Absence of a role of polymorphonuclear leukocyte
Topics: Animals; Collateral Circulation; Coronary Circulation; Detergents; Drug Combinations; Fluorocarbons; Hydroxyethyl Starch Derivatives; Infusions, Intravenous; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Neutrophils; Oxygen; Peroxidase; Poloxalene; Rabbits | 1994 |
Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function.
Topics: Animals; Chemotaxis, Leukocyte; Collateral Circulation; Coronary Circulation; Coronary Disease; Dogs; Gases; Heart; Infusions, Intravenous; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Necrosis; Neutrophils; Poloxalene; Ventricular Fibrillation; Ventricular Function, Left | 1994 |
Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model.
Topics: Animals; Coronary Circulation; Dogs; Drug Therapy, Combination; Mannitol; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Poloxalene | 1991 |